FDG-PET/CT of Giant Cell Arteritis with Normal Inflammatory Markers
Ann Neurol 92:337-339, Koizumi, N.,et al, 2022
Links in the Chain of Chronic Traumatic Encephalopathy
NEJM 380:1771-1772, Ropper, A.H., 2019
Prevalence of Cerebral Amyloid Pathology in Persons without Dementia
JAMA 313-1924-1938,1913, Jansen, W.J.,et al, 2015
Prevalence of Amyloid PET Positivity in Dementia Syndromes
JAMA 313:1939-1949,1913, Ossenkoppele, R.,et al, 2015
Progressive Cerebellar Ataxia and New-Onset Diabetes
Lancet 383:186, Kong, M.,et al, 2014
PET Imaging for Alzheimer Disease: Are Its Benefits Worth the Cost?
JAMA 309:1099-1100, Mitka, M., 2013
�-Amyloid Burden in Healthy Aging
Neurol 78:387-395, Rodrigue,K.M.,et al, 2012
Subjective Cognition and Amyloid Deposition Imaging
Arch Neurol 69:223-229, Perrotin,A.,et al, 2012
Predicting sites of New Hemorrhage with Amyloid Imaging in Cerebral Amyloid Angiopathy
Neurol 79:320-326, Gurol, M.E.,et al, 2012
Brain Amyloid Imaging - FDA Approval of Florbetapir F18 Injection
NEJM 367:885-887, Yang, L.,et al, 2012
Longitudinal Assessment of A-beta and Cognition in Aging and Alzheimer Disease
Ann Neurol 69:181-192, Villemagne,V.L.,et al, 2011
Changing Concepts of Alzheimer Disease
JAMA 35:2458-2459, McKhann, G.M., 2011
Treat Alzheimer Disease Before It Is Symptomatic
Arch Neurol 68:1237-1238, , 2011
Longitudinal Change of Biomakers in Cognitive Decline
Arch Neurol 68:1257-1266,1237, Lo, R.Y.,et al, 2011
Positron Emission Tomography-Computed Tomography in Paraneoplastic Neurologic Disorders: Systematic Analysis and Review
Arch Neurol 67:322-329, McKeon,A.,et al, 2010
Combining MR Imaging, Positron-Emission Tomography, and CSF Biomarkers in the Diagnosis and Prognosis of Alzheimers Disease
AJNR 31:347-354, Walhovd, K.B.,et al, 2010
In Vivo Mapping of Amyloid Toxicity in Alzheimer Disease
Neurol 72:1504-1511, Frisoni,B.G.,et al, 2009
Conversion of Amyloid Positive and Negative MCI to AD over 3 Years: An 11C-PIB PET Study
Neurol 73:754-760, 744, Okello,A.,et al, 2009
Pittsburg Compound B Imaging and Prediction of Progression From Cognitive Normality to Symptomatic Alzheimer Disease
Arch Neurol 66:1469-1475, Morris,J.,et al, 2009
Acute Limbic Encephalitis and Glutamic Acid Decarboxylase Antibodies:A Reality?
J Neurosci 287:69-71, Blanc,F.,et al, 2009
Assessment of �-Amyloid in a Frontal Cortical Brain Biopsy Specimen and by Positron Emission Tomography with Carbon 11-Labeled Pittsburgh Compound B
Arch Neurol 65:1304-1309,1281, Leinonen,V.,et al, 2008
Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the Elderly
Arch Neurol 65:1509-1517, Aizenstein,H.J.,et al, 2008
Imaging of Amyloid Burden and Distribution in Cerebral Amyloid Angiopathy
Ann Neurol 62:229-234, Johnson,K.A.,et al, 2007
Multiple Diagnostic Tests Are Needed to Assess Multiple Causes of Dementia
Arch Neurol 63:144-146,146, Rikkert,M.G.M.O.,et al, 2006
Episodic Neurologic Dysfunction with Migraine and Reversible Imaging Findings After RadiationRRH
Neurol 67:676-678, Pruitt,A.,et al, 2006
PET of Brain Amyloid and Tau in Mild Cognitive Impairment
NEJM 355:2652-2663, Small,G.W.,et al, 2006
Neuroimaging and Early Diagnosis of Alzheimer Disease: A Look to the Future
Radiology 226:315-336, Petrella,J.R.,et al, 2003
Dementia in Down's Syndrome:Cerebral Glucose Utilization, Neuropsychological Assessment, and Neuropathology
Neurol 38:938-942, Schapiro,M.B.,et al, 1988
Alzheimer's Disease
NEJM 314:964-973, Katzman,R., 1986